An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults

反应性 医学 接种疫苗 流感疫苗 免疫学 中和抗体 病毒学 甲型流感病毒 抗体 内科学 免疫 病毒
作者
Alicia T. Widge,Amelia Ruth Hofstetter,Katherine V. Houser,Seemal F. Awan,Grace L. Chen,Maria Claudia Burgos Florez,Nina M. Berkowitz,Floreliz H. Mendoza,Cynthia Starr Hendel,LaSonji A. Holman,Ingelise J. Gordon,Preeti Apte,C. Jason Liang,Martin Robert Gaudinski,Emily E. Coates,Larisa Strom,Diane L. Wycuff,Sandra Vazquez,Judy Stein,Jason G. D. Gall
出处
期刊:Science Translational Medicine [American Association for the Advancement of Science]
卷期号:15 (692): eade4790-eade4790 被引量:98
标识
DOI:10.1126/scitranslmed.ade4790
摘要

Influenza vaccines could be improved by platforms inducing cross-reactive immunity. Immunodominance of the influenza hemagglutinin (HA) head in currently licensed vaccines impedes induction of cross-reactive neutralizing stem-directed antibodies. A vaccine without the variable HA head domain has the potential to focus the immune response on the conserved HA stem. This first-in-human dose-escalation open-label phase 1 clinical trial (NCT03814720) tested an HA stabilized stem ferritin nanoparticle vaccine (H1ssF) based on the H1 HA stem of A/New Caledonia/20/1999. Fifty-two healthy adults aged 18 to 70 years old enrolled to receive either 20 μg of H1ssF once ( n = 5) or 60 μg of H1ssF twice ( n = 47) with a prime-boost interval of 16 weeks. Thirty-five (74%) 60-μg dose participants received the boost, whereas 11 (23%) boost vaccinations were missed because of public health restrictions in the early stages of the COVID-19 pandemic. The primary objective of this trial was to evaluate the safety and tolerability of H1ssF, and the secondary objective was to evaluate antibody responses after vaccination. H1ssF was safe and well tolerated, with mild solicited local and systemic reactogenicity. The most common symptoms included pain or tenderness at the injection site ( n = 10, 19%), headache ( n = 10, 19%), and malaise ( n = 6, 12%). We found that H1ssF elicited cross-reactive neutralizing antibodies against the conserved HA stem of group 1 influenza viruses, despite previous H1 subtype head-specific immunity. These responses were durable, with neutralizing antibodies observed more than 1 year after vaccination. Our results support this platform as a step forward in the development of a universal influenza vaccine.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小七完成签到,获得积分20
刚刚
星星在呼唤完成签到,获得积分10
1秒前
小蘑菇的应助被君子之昔采纳,获得10
1秒前
慕青的应助被林深见雾采纳,获得10
1秒前
fancy发布了新的文献求助10
1秒前
2秒前
大模型的应助被聚乙二醇采纳,获得10
2秒前
2秒前
ray101023完成签到,获得积分10
3秒前
大雪纷纷完成签到,获得积分10
4秒前
斯文败类的应助被聚乙二醇采纳,获得10
5秒前
cc发布了新的文献求助10
6秒前
6秒前
7秒前
wanci的应助被MYJ采纳,获得10
7秒前
顾矜的应助被聚乙二醇采纳,获得10
7秒前
小红发布了新的文献求助10
7秒前
8秒前
qugo完成签到,获得积分10
8秒前
8秒前
DDY发布了新的文献求助10
8秒前
玛丽完成签到,获得积分10
10秒前
ppp发布了新的文献求助10
10秒前
Orange的应助被聚乙二醇采纳,获得10
10秒前
10秒前
11秒前
深情安青的应助被baire采纳,获得10
11秒前
ding的应助被聚乙二醇采纳,获得10
13秒前
13秒前
洁净雁芙完成签到,获得积分10
13秒前
冯习发布了新的文献求助10
14秒前
15秒前
在水一方的应助被聚乙二醇采纳,获得10
15秒前
洪豆豆发布了新的文献求助30
15秒前
洪豆豆发布了新的文献求助10
15秒前
洪豆豆发布了新的文献求助10
16秒前
领导范儿的应助被谨慎的秋烟采纳,获得10
16秒前
音游诗人发布了新的文献求助10
16秒前
Huimin关注了科研通微信公众号
17秒前
Arrebol完成签到,获得积分10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Markov Decision Processes and Reinforcement Learning 700
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8170973
求助须知:如何正确求助?哪些是违规求助? 9563727
关于积分的说明 21771951
捐赠科研通 7762452
什么是DOI,文献DOI怎么找? 3430786
关于科研通互助平台的介绍 2554629
邀请新用户注册赠送积分活动 2475637